Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy.
暂无分享,去创建一个
M. Baccarani | H. Kantarjian | B. Druker | J. Lipton | D. Niederwieser | R. Stone | R. Silver | A. Countouriotis | T. Facon | A. Hochhaus | N. Shah | S. Goldberg | T. Hughes | F. Cervantes | J. Apperley | R. Ezzeddine | M. C. Muller | T. Hughes
[1] Francisco Cervantes,et al. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. , 2006, Blood.
[2] R. Larson,et al. Long-term benefits of imatinib (IM) for patients newly diagnosed with chronic myelogenous leukemia in chronic phase (CML-CP): The 5-year update from the IRIS study. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] Susan O'Brien,et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. , 2006, The New England journal of medicine.
[4] J. Cayuela,et al. Mutation status and clinical outcome of 89 imatinib mesylate-resistant chronic myelogenous leukemia patients: a retrospective analysis from the French intergroup of CML (Fi(ϕ)-LMC GROUP) , 2006, Leukemia.
[5] J. Rosen,et al. Stem cells in the etiology and treatment of cancer. , 2006, Current opinion in genetics & development.
[6] M. Deininger,et al. Chronic myeloid leukemia in 2006 : a perspective , 2006 .
[7] T. Hughes,et al. Molecular monitoring of BCR-ABL as a guide to clinical management in chronic myeloid leukaemia. , 2006, Blood reviews.
[8] C. Sawyers,et al. Five Year Follow-Up Results of a Phase II Trial in Patients with Late Chronic Phase (L-CP) Chronic Myeloid Leukemia (CML) Treated with Imatinib Who Are Refractory/Intolerant of Interferon-α. , 2005 .
[9] J. Mestan,et al. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. , 2005, Cancer research.
[10] Martin C. Müller,et al. Response and resistance in 300 patients with BCR‐ABL–positive leukemias treated with imatinib in a single center , 2005, Cancer.
[11] B. Druker,et al. Oncogenes and Tumor Suppressors (795 articles) , 2004 .
[12] C. Sawyers,et al. Comparative analysis of two clinically active BCR-ABL kinase inhibitors reveals the role of conformation-specific binding in resistance. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[13] Donna Neuberg,et al. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. , 2005, Cancer cell.
[14] Munir Pirmohamed,et al. Active transport of imatinib into and out of cells: implications for drug resistance. , 2004, Blood.
[15] J. Tokarski,et al. The Crystal Structure of Abl Kinase with BMS-354825, a Dual SRC/ABL Kinase Inhibitor. , 2004 .
[16] Yun Dai,et al. A Bcr/Abl-independent, Lyn-dependent Form of Imatinib Mesylate (STI-571) Resistance Is Associated with Altered Expression of Bcl-2* , 2004, Journal of Biological Chemistry.
[17] Ping Chen,et al. Overriding Imatinib Resistance with a Novel ABL Kinase Inhibitor , 2004, Science.
[18] A. Hochhaus,et al. Clinical resistance to imatinib: mechanisms and implications. , 2004, Hematology/oncology clinics of North America.
[19] Krzysztof Jamroziak,et al. Pharmacogenomics of MDR1/ABCB1 Gene: the Influence on Risk and Clinical Outcome of Haematological Malignancies , 2004, Hematology.
[20] G. Ehninger,et al. P-glycoprotein-mediated drug efflux is a resistance mechanism of chronic myelogenous leukemia cells to treatment with imatinib mesylate , 2004, Leukemia.
[21] Susan Branford,et al. Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis. , 2003, Blood.
[22] N. Donato,et al. BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571. , 2003, Blood.
[23] J. Kuriyan,et al. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. , 2002, Cancer cell.
[24] M. Baccarani,et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. , 2002, The New England journal of medicine.
[25] C. Peschel,et al. BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: a prospective study , 2002, The Lancet.
[26] B. Druker,et al. Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy , 2002, Leukemia.
[27] P. N. Rao,et al. Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification , 2001, Science.
[28] P. Blumberg,et al. RasGRP links T-cell receptor signaling to Ras. , 2000, Blood.
[29] C. Sawyers. Chronic myeloid leukemia. , 1999, The New England journal of medicine.
[30] C Chastang,et al. Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. French Chronic Myeloid Leukemia Study Group. , 1997, The New England journal of medicine.
[31] Sante Tura,et al. Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. , 1994, The New England journal of medicine.
[32] Ron Brookmeyer,et al. A Confidence Interval for the Median Survival Time , 1982 .